1. By my analysis, sarcoidosis is another indication showing promise of 300-400 scripts per quarter at 4-6 vials per script. Also opens up the pulmonologist market, who are similar to rheumatologists in that they can prescribe for a number of autoimmune/inflammatory disorders--and all will be 4-6 vial scripts in my opinion.
2. Rheumatology related scripts living up to their potential.
3. Analysts starting to raise target prices $5 to $8.
4. Sounds like a strong Q2 to me, leading into a knockout 2H.
The spike today was a bit disappointing given the level and immediacy of the news. But give it time and get rewarded. If we know anything about QCOR, it is this: immediate gratification is an elusive commodity.
Im shopping for popcorn toppings now to be ready for the 24th or 23rd or whenever it is! Each quarter is better and better. I am also shocked that todays news release didnt result in a greater spike... O well patience is a virtue they say